Publications

Thompson C, Perry C, Gaylor D, Tachovsky A, Burkhalter B, Haws L. Derivation of an oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. Presented at Society of Toxicology 50th Annual Meeting, Washington DC, March 2011.

Thompson CM, Proctor DM, Haws LC, Hebert CD, Grimes SD, Shertzer HG, Kopec AK, Hixon JG,  Zacharewski TR, Harris MA. 2011. Investigation of the mode of action underlying the tumorigenic response induced in B6C3F1 mice exposed orally to hexavalent chromium. Toxicol Sci 123(1):58-70; doi: 10.1093/toxsci/kfr164

Thompson CM, Haws LC, Harris MA, Gatto NM, Proctor DM. 2011. Application of the U.S. EPA mode of action framework for purposes of guiding future research: A case study involving the oral carcinogenicity of hexavalent chromium. Toxicol Sci 119(1):20-40; doi: 10.1093/toxsci/kfq320.

Thomas RS, Rowlands JC, Budinsky RA, Thompson CM, Urban JD. Dombkowski, A. 2011. Genomic approaches for relative potency assessment. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Wikoff DS, Thompson C, Walker N, DeVito M, Harris M, Birnbaum L, Haws L. Derivation of relative potency estimates using benchmark dose modeling: A case study with TCDF. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Thompson CM, Grafström RC. 2011. Considerations for the implausibility of leukemia induction by formaldehyde. Toxicol Sci 120(1):230-232; doi: 10.1093/toxsci/kfq340.

Ceder R, Merne M, Nilsson J-A, Staab C, Höög J-O, Thompson CM, Grafström RC. Toxicogenomic profiling of formaldehyde-exposed normal and transformed human oral keratinocytes. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

Haws L, Proctor D, Thompson C, Harris M. 2011. Research plan to fill data gaps in the mode of action for cancer risk assessment of hexavalent chromium in drinking water. Presented at the Society of Toxicology’s 50th Annual Meeting, March 6-10, Washington, D.C.

Wilson VS, Keshava N, Hester S, Segal D, Chiu W, Thompson CM, Euling SY. 2013. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol Appl Pharmacol 271(3):299–308; doi: 10.1016/j.taap.2011.01.017.

Kim S, Thompson CM, Kopec AK, Harris MA, Zacharewski TR. Comparison of basal and CrVI-mediated solute carrier gene expression in rodent duodenal epithelium. Presented at Society of Toxicology 50th Annual Meeting, Washington, D.C., March 2011.

Proctor D, Haws L, Thompson C, Harris M. 2011. Use of mode of action and pharmacokinetics to inform the cancer risk assessment of ingested Cr(VI): A case study. Presented at the Society of Toxicology 50th Annual Meeting, March 6-10, 2011, Washington, D.C.

Johns DO, Owens EO, Thompson CM, Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.

Thompson CM, Ceder R, Grafström RC. 2010. Formaldehyde dehydrogenase: Beyond phase I metabolism. Toxicol Lett 193(1):1-3; doi: 10.1016/j.toxlet.2009.11.023.

Thompson CM, Grafstrom RC. 2009. Commentary: Mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. Environ Health 8:53; doi: 10.1186/1476-069X-8-53.

Thompson CM, Sonawane B, Grafström RC. 2009. The ontogeny, distribution and regulation of alcohol dehydrogenase 3: Implications for pulmonary physiology. Drug Metab Disposit 37(8):1565-1571; doi: 10.1124/dmd.109.027904.

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.

DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 51(June):66–86; doi: 10.1016/j.yrtph.2008.02.005.

Makris SL, Thompson CM, Euling SY, Selevan SG, Sonawane B. 2008. A lifestage-specific spproach to hazard and dose-response characterization for children’s health risk assessment. Birth Defects Res B 83(6):530–546; doi: 10.1002/bdrb.20176.

Subramaniam RP, Chen C, Crump KS, Devoney D, Fox JF, Portier CJ, Schlosser PM, Thompson CM, White P. 2008. Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: Identification of key issues. Risk Analysis 28(4):907–923; doi: 10.1111/j.1539-6924.2008.01083.x.

Thompson CM, Subramaniam RP, Grafström RC. 2008. Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. Toxicol Appl Pharmacol 233(3):355–359.